Post-earnings recap
Reported
Thu, Jul 28, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Ultragenyx Pharmaceutical faced challenges in achieving expected earnings, leading to a negative surprise on EPS. Despite this, the stock rose by 2.11%, which may reflect investor optimism about the company's long-term potential or other positive developments discussed during the call. The lack of revenue data and guidance may leave investors cautious moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.26 | N/A | -31.40% |
| Revenue | N/A | N/A | N/A |
Management expressed concern over current financial performance while highlighting their commitment to improving operations. They did not provide any forward guidance, indicating uncertainty in future results.
Management acknowledged challenges in meeting EPS expectations.
They emphasized ongoing efforts to enhance operational efficiency.
No specific revenue guidance was provided for the upcoming quarters.